Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?
Fanale D, Corsini LR, Scalia R, Brando C, Cucinella A, Madonia G, Dimino A, Filorizzo C, Barraco N, Bono M, Fiorino A, Magrin L, Sciacchitano R, Perez A, Russo TDB, Pantuso G, Russo A, Bazan V.
Fanale D, et al. Among authors: corsini lr.
Crit Rev Oncol Hematol. 2022 Feb;170:103597. doi: 10.1016/j.critrevonc.2022.103597. Epub 2022 Jan 13.
Crit Rev Oncol Hematol. 2022.
PMID: 35033663
Review.